BioGenes to participate in EU funded dementia project
Berlin-based BioGenes, a specialist in sophisticated antibody development, has been chosen as a new partner of cNEUPRO.
Berlin-based BioGenes, a specialist in sophisticated antibody development, has been chosen as a new partner of cNEUPRO.
cNEUPRO is an EU-funded research project to analyse neurodegenerative diseases and discover novel biomarkers, and so improve early and differential diagnosis of Alzheimer's dementia.
BioGenes will provide laboratory facilities and key personnel to develop specific monoclonal antibodies against novel neurochemical dementia biomarkers in blood and cerebrospinal fluid that have been identified during the project. These monoclonal antibodies may be used not only for diagnostics, but may also have potential as therapeutic agents since they may access the CNS space.
Recent research has demonstrated that multi-parametric neurochemical dementia diagnostics (NDD) in cerebrospinal fluid does improve early and differential diagnosis of dementias.
cNEUPRO will establish European standard operation procedures (SOPs) for NDD and first NDD refer-ence centres in Portugal and Hungary. cNEUPRO unites the forces of nineteen biotech and bioinformatic companies as well as leading clinical and proteomic dementia research centres.